Australian Melanoma Research Foundation

Last updated
Australian Melanoma Research Foundation
Type Charity
FocusResearch, improving survival rates for cancer sufferers, preventive measures
Headquarters Adelaide, Australia
Area served
Australia
Website www.melanomaresearch.com.au

The Australian Melanoma Research Foundation participates in various activities to raise funds and raise awareness of melanoma. [1]

Related Research Articles

<span class="mw-page-title-main">Melanocytic nevus</span> Medical condition

A melanocytic nevus is usually a noncancerous condition of pigment-producing skin cells. It is a type of melanocytic tumor that contains nevus cells. Some sources equate the term mole with "melanocytic nevus", but there are also sources that equate the term mole with any nevus form.

<span class="mw-page-title-main">Skin cancer</span> Medical condition involving uncontrolled growth of skin cells

Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells that have the ability to invade or spread to other parts of the body. There are three main types of skin cancers: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. The first two, along with a number of less common skin cancers, are known as nonmelanoma skin cancer (NMSC). Basal-cell cancer grows slowly and can damage the tissue around it but is unlikely to spread to distant areas or result in death. It often appears as a painless raised area of skin that may be shiny with small blood vessels running over it or may present as a raised area with an ulcer. Squamous-cell skin cancer is more likely to spread. It usually presents as a hard lump with a scaly top but may also form an ulcer. Melanomas are the most aggressive. Signs include a mole that has changed in size, shape, color, has irregular edges, has more than one color, is itchy or bleeds.

<span class="mw-page-title-main">Danny Federici</span> American musician

Daniel Paul Federici was an American musician, best known as the organ, glockenspiel, and accordion player and a founding member of Bruce Springsteen's E Street Band. In 2014, Federici was posthumously inducted into the Rock and Roll Hall of Fame as a member of the E Street Band.

<span class="mw-page-title-main">Melanoma</span> Cancer originating in melanocytes

Melanoma, also redundantly known as malignant melanoma, is a type of skin cancer that develops from the pigment-producing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men, they most commonly occur on the back. About 25% of melanomas develop from moles. Changes in a mole that can indicate melanoma include an increase in size, irregular edges, change in color, itchiness, or skin breakdown.

<span class="mw-page-title-main">Andy Flower</span> Zimbabwean cricket player/coach

Andrew Flower is a Zimbabwean cricket coach and a former cricketer. As a cricketer, he captained the Zimbabwe national cricket team and is widely regarded as one of the greatest wicket-keeper-batters of all time. He was Zimbabwe's wicket-keeper for more than 10 years and is, statistically, the greatest batsman the country has produced. His highest score in ODI cricket which was his 145 he made against India in the 2002 ICC Champions Trophy is also the highest score made by a Zimbabwe player at any tournaments. During his peak from October to December 2001, Flower was ranked as the best Test batsman in the world. He was widely acknowledged as the only Zimbabwe batsman of proper test quality in any conditions. After retirement, he served as the coach of the English cricket team from 2009 to 2014. Under his coaching, England won the 2010 ICC World Twenty20. Flower became the second foreign coach in the team's history. Currently, he is the head coach of Multan Sultans in the Pakistan Super League, St Lucia Kings in the Caribbean Premier League and the Lucknow Super Giants in Indian Premier League.

<span class="mw-page-title-main">Acral lentiginous melanoma</span> Medical condition

Acral lentiginous melanoma is an aggressive type of skin cancer. Melanoma is a group of serious skin cancers that arise from pigment cells (melanocytes); acral lentiginous melanoma is a kind of lentiginous skin melanoma. Acral lentiginous melanoma is the most common subtype in people with darker skins and is rare in people with lighter skin types. It is not caused by exposure to sunlight or UV radiation, and wearing sunscreen does not protect against it. Acral lentiginous melanoma is commonly found on the palms, soles, under the nails, and in the oral mucosa. It occurs on non-hair-bearing surfaces of the body, which have not necessarily been exposed to sunlight. It is also found on mucous membranes.

<span class="mw-page-title-main">Dysplastic nevus</span> Medical condition

A dysplastic nevus or atypical mole is a nevus (mole) whose appearance is different from that of common moles. In 1992, the NIH recommended that the term "dysplastic nevus" be avoided in favor of the term "atypical mole". An atypical mole may also be referred to as an atypical melanocytic nevus, atypical nevus, B-K mole, Clark's nevus, dysplastic melanocytic nevus, or nevus with architectural disorder.

<span class="mw-page-title-main">Dysplastic nevus syndrome</span> Medical condition

Dysplastic nevus syndrome, also known as familial atypical multiple mole–melanoma (FAMMM) syndrome, is an inherited cutaneous condition described in certain families, and characterized by unusual nevi and multiple inherited melanomas. First described in 1820, the condition is inherited in an autosomal dominant pattern, and caused by mutations in the CDKN2A gene. In addition to melanoma, individuals with the condition are at increased risk for pancreatic cancer.

<span class="mw-page-title-main">Lentigo maligna melanoma</span> Medical condition

Lentigo maligna melanoma is a melanoma that has evolved from a lentigo maligna, as seen as a lentigo maligna with melanoma cells invading below the boundaries of the epidermis. They are usually found on chronically sun damaged skin such as the face and the forearms of the elderly.

<span class="mw-page-title-main">Uveal melanoma</span> Type of eye cancer

Uveal melanoma is a type of eye cancer in the uvea of the eye. It is traditionally classed as originating in the iris, choroid, and ciliary body, but can also be divided into class I and class II. Symptoms include blurred vision, loss of vision or photopsia, but there may be no symptoms.

<span class="mw-page-title-main">Fotemustine</span> Chemical compound

Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA. A study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC. There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia and thrombocytopenia.

<span class="mw-page-title-main">Microphthalmia-associated transcription factor</span> Mammalian protein found in Homo sapiens

Microphthalmia-associated transcription factor also known as class E basic helix-loop-helix protein 32 or bHLHe32 is a protein that in humans is encoded by the MITF gene.

<span class="mw-page-title-main">CD146</span> Protein-coding gene in the species Homo sapiens

CD146 also known as the melanoma cell adhesion molecule (MCAM) or cell surface glycoprotein MUC18, is a 113kDa cell adhesion molecule currently used as a marker for endothelial cell lineage. In humans, the CD146 protein is encoded by the MCAM gene.

<span class="mw-page-title-main">Melanotransferrin</span> Protein-coding gene in the species Homo sapiens

Melanotransferrin is a protein that in humans is encoded by the MFI2 gene. MFI2 has also recently been designated CD228.

CancerVax was an American pharmaceutical company founded in 1998 by Donald Morton. The company sought to develop a vaccine for cancer, and had candidates for melanoma reach phase III clinical trials. When those trials proved unsuccessful in 2005, the company soon underwent a reverse takeover with Micromet.

Mucosal melanoma is a rare condition characterized by a melanoma of the mucous membranes. This subtype is associated a worse prognosis than those arising from the skin. Mucosal melanomas occur in the head and neck (55%), anorectal (24%) and vulvovaginal region (18%), and in the urinary tract (3%). Based on the histopathologic and clinical features, melanomas of the vulva and vagina are often considered a separate disease entity. The prognosis of vulvovaginal melanomas is poor, especially for vaginal melanomas and has not improved over the last decades. While chemotherapy has not shown capacity to improve survival in clinical and observational studies, immune checkpoint inhibitors have been tested in mucosal melanomas and have shown promising response rates.

Skin cancer, or neoplasia, is the most common type of cancer diagnosed in horses, accounting for 45 to 80% of all cancers diagnosed. Sarcoids are the most common type of skin neoplasm and are the most common type of cancer overall in horses. Squamous-cell carcinoma is the second-most prevalent skin cancer, followed by melanoma. Squamous-cell carcinoma and melanoma usually occur in horses greater than 9-years-old, while sarcoids commonly affect horses 3 to 6 years old. Surgical biopsy is the method of choice for diagnosis of most equine skin cancers, but is contraindicated for cases of sarcoids. Prognosis and treatment effectiveness varies based on type of cancer, degree of local tissue destruction, evidence of spread to other organs (metastasis) and location of the tumor. Not all cancers metastasize and some can be cured or mitigated by surgical removal of the cancerous tissue or through use of chemotherapeutic drugs.

<span class="mw-page-title-main">Trametinib</span> Anticancer medication

Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2. It is taken by mouth.

<span class="mw-page-title-main">Talimogene laherparepvec</span>

Talimogene laherparepvec, sold under the brand name Imlygic, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer. The final four year analysis from the pivotal phase 3 study upon which TVEC was approved by the FDA showed a 31.5% response rate with a 16.9% complete response (CR) rate. There was also a substantial and statistically significant survival benefit in patients with earlier metastatic disease and in patients who hadn't received prior systemic treatment for melanoma. The earlier stage group had a reduction in the risk of death of approximately 50% with one in four patients appearing to have met, or be close to be reaching, the medical definition of cure. Real world use of talimogene laherparepvec have shown response rates of up to 88.5% with CR rates of up to 61.5%.

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.

References

  1. "Rachael Sporn launches first SA march against skin cancer with help from Andrew Jarman and Luke Schenscher". Adelaidenow.com.au. Retrieved 2016-01-20.